Analysts Slash Y-mAbs Therapeutics Worth Targets As Uncertainty Looms Over Neuroblastoma Hopeful

• On Friday, FDA’s Oncologic Medicine Advisory Committee (ODAC) voted 16 to 0 that Y-mAbs Therapeutics Inc (NASDAQ: YMAB) didn’t present ample proof to conclude that omburtamab improves total survival.

• Guggenheim says the information is disappointing, slashing the value goal from $26 to $18, given the unlikelihood of a precedence overview voucher price round $70 million in internet proceeds and the present money runway into mid-2024. The analyst maintained the Purchase ranking on the inventory.

• The analyst notes omburtamab was a comparatively minor worth driver, with round $20 million within the U.S. peak gross sales for the lead indication.

• Pipeline focus will possible shift to GD2-SADA, the place YMAB goals to provoke dosing by YE 2022 and supply preliminary imaging information from ~5-10 sufferers by 2H 2023.

• HC Wainwright lowered the worth goal for YMAB from $63 to $19 and maintained a Purchase ranking.

• The analyst says that Y-mAbs demonstrated the validity of the strategy embodied by omburtamab, however this candidate faces an unsure future, and it can’t be assured of Y-mAbs’ dedication or potential to deal with the considerations raised by the FDA’s advisory committee.

• HC Wainwright expects the FDA to subject a Full Response Letter throughout the coming weeks.

• Worth Motion: YMAB shares are down 56.56% at $3.90 on the final verify Monday.

Newest Scores for YMAB

View Extra Analyst Scores for YMAB

View the Newest Analyst Scores

See extra from Benzinga

Do not miss real-time alerts in your shares – be part of Benzinga Professional without cost! Attempt the instrument that can enable you make investments smarter, sooner, and higher.

© 2022 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.